^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Ganfule

Associations
Trials
Company:
China Medical System
Drug class:
DNA synthesis inhibitor, Immunomodulator
Related drugs:
Associations
Trials
2years
Ganfule capsule alleviates bile duct ligation-induced liver fibrosis in mice by inhibiting glutamine metabolism. (PubMed, Front Pharmacol)
This study confirms the protective effect of GFL on liver injury and shows that GFL inhibits glutamine metabolism, which was correlated with the NF-κB pathway, and eventually alleviates liver fibrosis. These results are conducive to the development of new therapeutic drugs for liver fibrosis.
Preclinical • Journal
|
GLS1 (Glutaminase) • RELA (RELA Proto-Oncogene)
|
Ganfule
3years
Effects of Ganfule Capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma. (PubMed, J Appl Microbiol)
This study is the first to report the anti-HCC effect of GFL associated with gut microbiota and plasma metabolites. GFL may improve the gut microbiota structure, such as increasing probiotics - Lactobacillus. It also provides a new strategy for the scientific demonstration of the modernization of traditional Chinese medicine.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
Ganfule